Protein fluorescence explored for cataract diagnosis

Article

Fluorescence of lens proteins could help understand, diagnose, and treat cataracts, researchers say.“Rather than waiting for the condition to appear, it could be possible to diagnose and monitor cataract before it forms, allowing preventative measures to be taken where possible,” said Rory Duncan of Heriot-Watt University in Edinburh, United Kingdom in a press release.

Fluorescence of lens proteins could help understand, diagnose, and treat cataracts, researchers say.

“Rather than waiting for the condition to appear, it could be possible to diagnose and monitor cataract before it forms, allowing preventative measures to be taken where possible,” said Rory Duncan of Heriot-Watt University in Edinburh, United Kingdom in a press release.

Duncan and colleagues published their findings in Nature Scientific Reports.

The research focuses on post-translational modifications (PTMs) of Trp and Arg amino acid residues that accumulate as lenses age.

Courtesy of Dr Rory Duncan

Current cataract diagnosis depends on light scattering methods which can detect defects in the lens structure when they reach at least 0.5 µm, the optical wavelength. But the formation of PTMs may precede the micron-sized defects that make these light-scattering methods possible.

Matured eye lens fibre cells do not contain organelles apart from the proteasome, Duncan and colleagues point out. This gives the eye lens optical homogeneity and minimizes Rayleigh scattering. But it also precludes the synthesis of new proteins.

Courtesy of Dr Rory DuncanAs a result, proteins synthesised in new cells remain throughout the lifespan of mature cells. Without protein turnover, PTMS accumulate in crystallins, resulting in protein misfolding and aggregation and causing light scattering.

Also, some PTMS absorb light in the visible spectral range, reducing lens transparency and giving rise to coloration.

Modifications of Trp side chains can change the position of the Trp emission spectrum and fluorescence. So the researchers hypothesized that formation PTMs in crystallins endows the eye lens a unique fluorescence “signature” that could be measurable.

Exploring PTM fluorescence

 

To explore this proposition, Duncan and colleagues examined the fluorescence of PTMs in lenses from pigs and in donated human lenses.

They found that due to the spectral selectivity on the red edge of the Trp absorption spectrum, they could excite a fraction of Trp residues situated in hydrophilic pockets with a red-shifted absorption spectrum. A 317 nm light-emitting diode (LED) was effective for this excitation. They also measured fluorescence from Trp photo-degradation products and ArgP.

Courtesy of Dr Rory Duncan

They compared pig lenses irradiated with ultraviolet light to untreated lenses. And they compared human lenses from an eye bank, post-operational phaco-emulsified lens samples and clear emulsified lenses of 40 and 46 year old patients who underwent cosmetic surgery.

“The technology identifies how much oxidative damage lens proteins have accumulated through lifestyle or environmental factors,” said Duncan in the press release. “This accumulated damage may be important in determining risk factors for a number of age-related conditions.”

In summarizing, they wrote that they had developed a novel non-invasive method of semi-quantitative determination of the concentrations of fluorescent PTMs in the lens based on simultaneous measurements of fluorescence emission.

“We show that the fluorescence spectra of the individual fluorescent components normalised against Trp intensity enable determination of their relative concentration with an accuracy of 5–10%,” they wrote. “This makes this method useful for cataract grading and for monitoring cataractogenesis over a period of time.”

By monitoring changes in the lens structure at the molecular level, the hoped to also facilitate the development of medications that might slow down the development of cataracts.

 

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
© 2025 MJH Life Sciences

All rights reserved.